Main menu
Edison Group
  • Home
  • Sparks
  • Equities

    Equities

    View All Equities

    Equities by Sector

    YXT.com

    MCap

    USD127m

    Last close

    USD23.43

    ▲ 20.23 (632.19%)

    Northern Data Group

    MCap

    EUR486m

    Last close

    EUR7.56

    ▲ 2.33 (44.59%)

    Bodycote

    MCap

    GBP1,572m

    Last close

    GBP9.23

    ▲ 173.00 (23.07%)

  • Sectors

    Sectors

  • Megatrends

    Megatrends

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Executive interview with Carlos Buesa, CEO of Oryzon Genomics

Executive interview with Carlos Buesa, CEO of Oryzon Genomics

Oryzon Genomics — 8 videos in collection

More on this equity

Spanish biotech Oryzon Genomics is among the leading clinical-stage drug developers, with a second generation of epigenetic therapeutics that have greater selectivity and a potentially favourable safety/efficacy profile compared with the first-generation HDAC inhibitors. Oryzon is focused on epigenetics in oncology and the central nervous system (CNS). Iadademstat is being explored for acute leukaemias, small-cell lung cancer (SCLC) and neuroendocrine tumours. CNS asset vafidemstat has completed several Phase IIa trials and a Phase IIb trial in borderline personality disorder is now the lead study.

In this interview, Oryzon CEO Carlos Buesa recaps the company’s pipeline and provides a preview of the upcoming rich newsflow.

< Previous
Next >

You may also be interested in these:

Healthcare

Oryzon Genomics – executive interview

Healthcare

Oryzon Genomics – equity proposition
Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.